Use of an RXR agonist in treating drug resistant HER2+ cancers
AssigneesIo Therapeutics, Inc., Board of Regents, The University of Texas System
InventorsMartin E. Sanders, Powel H. Brown, Cassandra Moyer, Abhijit Mazumdar
Life of this patent
Estimating the term…
Abstract
The present specification provides combinations of active agents for the improved treatment of Her2+ cancers and associated methods of treatments. The combinations comprise an RXR agonist and a Her2-targeted therapeutic agent and may optionally further comprise thyroid hormone.
Claims23
A method of treating a patient with Her2+ cancer resistant to at least one Her2-targeted therapeutic agent, the method comprising administering a retinoid X receptor (RXR) agonist of Formula I
- wherein R is H, or lower alkyl of 1 to 6 carbons, or a pharmaceutically-acceptable salt thereof, to the patient;
- wherein the Her2+ cancer resistant to a Her2-targeted therapeutic agent is also resistant to the RXR agonist of Formula I;
- and
- the patient has received or is receiving the Her2-targeted therapeutic agent.
A method of treating a patient with Her2+ cancer undergoing treatment with a Her2-targeted therapeutic agent, wherein the cancer has become resistant to the Her2-targeted therapeutic agent, the method comprising continuing treatment with the Her2-targeted therapeutic agent and initiating treatment with an RXR agonist of Formula I,
- wherein R is H, or lower alkyl of 1 to 6 carbons, or a pharmaceutically-acceptable salt thereof;
- and
- wherein the Her2+ cancer resistant to a Her2-targeted therapeutic agent is also resistant to the RXR agonist of Formula I.
Dependencies are inferred from the claim text.